| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Cyclin-dependent kinase 7 |
|---|
| Ligand | BDBM81438 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | In Vitro Kinase Assay |
|---|
| Ki | 940±55 nM |
|---|
| Citation |  Wang, S; Griffiths, G; Midgley, CA; Barnett, AL; Cooper, M; Grabarek, J; Ingram, L; Jackson, W; Kontopidis, G; McClue, SJ; McInnes, C; McLachlan, J; Meades, C; Mezna, M; Stuart, I; Thomas, MP; Zheleva, DI; Lane, DP; Jackson, RC; Glover, DM; Blake, DG; Fischer, PM Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol17:1111-21 (2010) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Cyclin-dependent kinase 7 |
|---|
| Name: | Cyclin-dependent kinase 7 |
|---|
| Synonyms: | 39 kDa protein kinase | CAK | CAK1 | CDK-activating kinase | CDK-activating kinase 1 (CAK) | CDK7 | CDK7_HUMAN | CDKN7 | Cell division protein kinase 7 | Cyclin-Dependent Kinase 7 (CDK7) | Cyclin-dependent kinase 7 (CDK7/cyclin H) | MO15 | P39 Mo15 | STK1 | TFIIH basal transcription factor complex kinase subunit |
|---|
| Type: | Enzyme Subunit |
|---|
| Mol. Mass.: | 39047.01 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | n/a |
|---|
| Residue: | 346 |
|---|
| Sequence: | MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTAL
REIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLM
TLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRA
PELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDM
CSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPG
PTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF
|
|
|
|---|
| BDBM81438 |
|---|
| n/a |
|---|
| Name | BDBM81438 |
|---|
| Synonyms: | CDK Inhibitor, 11 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C18H21N5O4S2 |
|---|
| Mol. Mass. | 435.52 |
|---|
| SMILES | COCCNS(=O)(=O)c1ccc(Nc2nccc(n2)-c2sc(=O)n(C)c2C)cc1 |
|---|
| Structure | 
|
|---|
Search and Browse
